[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease


Description

The main purpose of this study is to investigate the efficacy and safety of Volenrelaxin in adults with Chronic Kidney Disease. The study will last about 12 weeks.

Trial Eligibility

Inclusion Criteria: * Have a diagnosis of Chronic Kidney Disease (CKD) based on eGFR category and albuminuria category per the Kidney Disease: Improving Global Outcomes (KDIGO) criteria * Have been on a maximally tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) for 90 days preceding screening and is expected to remain on a stable regimen through the study * If on additional treatment for CKD, must be on stable dose for at least 90 days before screening. * If diagnosed with Type 2 Diabetes, should be on stable antihyperglycemic treatment for at least 90 days before screening. Exclusion Criteria: * Have any one of the following cardiovascular conditions 90 days prior to screening: * myocardial infarction * stroke * hospitalization or urgent visit for heart failure, and * coronary, carotid, or peripheral artery revascularization. * Have a documented New York Heart Association (NYHA) Class IV heart failure at the time of screening. * Have chronic or intermittent hemodialysis or peritoneal dialysis 90 days prior to screening. * Have acute dialysis or acute kidney injury 90 days prior to screening. * Have a history of a congenital or hereditary kidney disease, polycystic kidney disease, lupus nephritis, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and nephrotic syndrome * Requires chronic immunosuppression. * Have HbA1c \>8.5% at screening * Have had a transplanted organ or are awaiting an organ transplant * Have a diagnosis or history of malignant disease within 5 years prior to baseline. * Have symptomatic hypotension. * Have acute or chronic hepatitis.

Study Info

Organization

Eli Lilly and Company


Primary Outcome

Percent Change from Baseline of Urine Albumin-Creatinine Ratio (UACR)


Outcome Timeframe Baseline, Week 12

NCTID NCT06598631

Phases PHASE2

Primary Purpose TREATMENT

Start Date 2024-10-09

Completion Date 2026-02

Enrollment Target 280

Interventions

DRUG Volenrelaxin

DRUG Placebo

Locations Recruiting

Diabetes and Metabolism Associates, APMC

United States, Louisiana, Metairie


Elite Clinical Research Center

United States, Michigan, Flint


Lucas Research, Inc.

United States, North Carolina, Morehead City


Eastern Nephrology Associates- New Bern Office Loc. 1

United States, North Carolina, New Bern


Endocrine Associates

United States, Texas, Houston


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Kidney Disease delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.